Sigilon Therapeutics, Inc.

Informe acción NasdaqGS:SGTX

Capitalización de mercado: US$56.5m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Sigilon Therapeutics Dirección

Dirección controles de criterios 3/4

We currently do not have sufficient information about the CEO.

Información clave

Rogerio Coelho

Chief Executive Officer (CEO)

US$2.0m

Compensación total

Porcentaje del salario del CEO29.7%
Permanencia del CEO5.6yrs
Participación del CEOn/a
Permanencia media de la dirección2.3yrs
Promedio de permanencia en la Junta Directiva5.7yrs

Actualizaciones recientes de la dirección

Recent updates

Benign Growth For Sigilon Therapeutics, Inc. (NASDAQ:SGTX) Underpins Stock's 34% Plummet

Apr 17
Benign Growth For Sigilon Therapeutics, Inc. (NASDAQ:SGTX) Underpins Stock's 34% Plummet

Sigilon Therapeutics GAAP EPS of -$0.44, revenue of $2.88M

Aug 04

Sigilon Therapeutics names Philip Ashton-Rickardt as chief scientific officer

Jun 14

What Percentage Of Sigilon Therapeutics, Inc. (NASDAQ:SGTX) Shares Do Insiders Own?

Mar 04
What Percentage Of Sigilon Therapeutics, Inc. (NASDAQ:SGTX) Shares Do Insiders Own?

Sigilon Therapeutics' MPS-1 gene therapy an Orphan Drug in U.S.

Dec 17

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Rogerio Coelho en comparación con los beneficios de Sigilon Therapeutics?
FechaCompensación totalSalarioIngresos de la empresa
Jun 30 2023n/an/a

-US$30m

Mar 31 2023n/an/a

-US$37m

Dec 31 2022US$2mUS$601k

-US$44m

Sep 30 2022n/an/a

-US$55m

Jun 30 2022n/an/a

-US$66m

Mar 31 2022n/an/a

-US$72m

Dec 31 2021US$6mUS$578k

-US$77m

Sep 30 2021n/an/a

-US$75m

Jun 30 2021n/an/a

-US$68m

Mar 31 2021n/an/a

-US$61m

Dec 31 2020US$810kUS$528k

-US$55m

Sep 30 2020n/an/a

-US$52m

Jun 30 2020n/an/a

-US$51m

Mar 31 2020n/an/a

-US$47m

Dec 31 2019US$723kUS$508k

-US$44m

Compensación vs. Mercado: Rogerio's total compensation ($USD2.02M) is above average for companies of similar size in the US market ($USD754.53K).

Compensación vs. Ingresos: Rogerio's compensation has been consistent with company performance over the past year.

CEO

Rogerio Coelho (59 yo)

5.6yrs

Permanencia

US$2,024,671

Compensación

Dr. Rogerio Vivaldi Coelho, M.D., M.B.A., is Independent Director of Crinetics Pharmaceuticals, Inc. from January 03, 2022. He was Chief Global Therapeutic Operations Officer and Executive Vice President o...

Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Rogerio Coelho
President5.6yrsUS$2.02msin datos
Philip Ashton-Rickardt
Chief Scientific Officer2.2yrsUS$902.19k0%
$ 0
Robert Langer
Co-Founder & Member of Scientific Advisory Boardno dataUS$101.90ksin datos
Daniel Anderson
Co-Founder & Member of Scientific Advisory Boardno dataUS$46.92ksin datos
Omid Veiseh
Co-Founderno datasin datossin datos
José Oberholzer
Co-Founderno datasin datossin datos
Arturo Vegas
Co-Founderno datasin datossin datos
Josias Fantato Pontes
CFO, Principal Accounting Officer & Treasurer1.5yrssin datos0%
$ 0
Bernd Kullmann
Senior VP and Head of Operations & Project Managementless than a yearsin datossin datos
Matthew Kowalsky
Chief of Staff3.6yrssin datos0%
$ 0
Robert Windsor
VP & Head of Investor Relations2.3yrssin datossin datos
Olivia Kelly
Senior VP & Head of Diabetes Research5.6yrssin datossin datos

2.3yrs

Permanencia media

57.5yo

Promedio de edad

Equipo directivo experimentado: SGTX's management team is considered experienced (2.3 years average tenure).

Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Rogerio Coelho
President5.6yrsUS$2.02msin datos
Robert Langer
Co-Founder & Member of Scientific Advisory Boardno dataUS$101.90ksin datos
Daniel Anderson
Co-Founder & Member of Scientific Advisory Boardno dataUS$46.92ksin datos
Michael Rosenblatt
Member of Scientific Advisory Board3.6yrssin datossin datos
Ulrik Nielsen
Member of Scientific Advisory Board3.6yrssin datossin datos
Stephen Newman Oesterle
Independent Director7.6yrsUS$51.24k0%
$ 0
Robert R. Ruffolo
Independent Director7.6yrsUS$44.74k0%
$ 0
Douglas Cole
Independent Chairman of The Board8.6yrsUS$87.74k0%
$ 0
John Cox
Independent Director4.3yrsUS$44.74k0%
$ 0
Constance Cepko
Member of Scientific Advisory Board5.8yrssin datossin datos
Eric Shaff
Independent Director5.8yrsUS$54.74k0%
$ 0
Kavita Patel
Independent Director3.2yrsUS$45.80k0%
$ 0

5.7yrs

Permanencia media

60yo

Promedio de edad

Junta con experiencia: SGTX's board of directors are considered experienced (5.7 years average tenure).